TrialLancet (London, England)2018

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Juan Pablo Frias et al.PubMed ↗Publisher ↗

No numbers read from the abstract.